title: Cytogenetic features of de novo CD5-positive diffuse large B-cell lymphoma: chromosome aberrations affecting 8p21 and 11q13 constitute major subgroups with different overall survival.
abstract: De novo CD5-positive diffuse large B-cell lymphoma (CD5(+)DLBCL) is regarded as a different clinicopathological entity from CD5-negative DLBCL (CD5(-)DLBCL) and mantle cell lymphoma (MCL). Because only a few published cytogenetic studies of de novo CD5(+)DLBCL are available, we investigated chromosomal changes in 23 Japanese patients who had de novo CD5(+)DLBCL. A characteristic of cytogenetic abnormalities in de novo CD5(+)DLBCL was a high incidence of chromosomal aberrations affecting 8p21 and 11q13. Major chromosomal breakpoints were concentrated at 8p21, 11q13, and 3q27. Patients with 8p21 aberrations showed aggressive clinical features, including advanced stage of disease, elevated serum LDH level, poor performance status, and an inferior survival curve compared with patients who had 11q13 changes (P = .043). Chromosomal abnormalities of both 8p21 and 11q13 were not observed in the same patient, and each abnormality showed different chromosomal gains and losses. These results indicate that de novo CD5(+)DLBCL may occur in previously unidentified subgroups that differ in their chromosomal abnormalities. The conflicting results of previous studies on prognosis may thus be explained in part by the differences in chromosomal changes.
authors.affiliation: Third Department of Internal Medicine, Akita University School of Medicine, Akita, Japan.
authors.forename: Tomoko
authors.initials: T
authors.lastname: Yoshioka
authors.forename: Ikuo
authors.initials: I
authors.lastname: Miura
authors.forename: Masaaki
authors.initials: M
authors.lastname: Kume
authors.forename: Naoto
authors.initials: N
authors.lastname: Takahashi
authors.forename: Masataka
authors.initials: M
authors.lastname: Okamoto
authors.forename: Ryo
authors.initials: R
authors.lastname: Ichinohasama
authors.forename: Tadashi
authors.initials: T
authors.lastname: Yoshino
authors.forename: Motoko
authors.initials: M
authors.lastname: Yamaguchi
authors.forename: Makoto
authors.initials: M
authors.lastname: Hirokawa
authors.forename: Ken-Ichi
authors.initials: K
authors.lastname: Sawada
authors.forename: Shigeo
authors.initials: S
authors.lastname: Nakamura
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D018956:CD5 Antigens / Q000235:genetics*; D002869:Chromosome Aberrations; D019457:Chromosome Breakage / Q000235:genetics; D002872:Chromosome Deletion; D002880:Chromosomes, Human, Pair 11 / Q000235:genetics*; D002898:Chromosomes, Human, Pair 8 / Q000235:genetics*; D003582:Cytogenetics / Q000379:methods*; D005260:Female; D005784:Gene Amplification / Q000235:genetics; D006801:Humans; D016403:Lymphoma, Large B-Cell, Diffuse / Q000235:genetics* / Q000401:mortality* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D015996:Survival Rate; D014178:Translocation, Genetic / Q000235:genetics
chemical_list: D018956:CD5 Antigens